Correlation of hs-CRP, Lp-PLA2, and S100β with vascular cognitive impairment in patients with ischemic small vascular disease

doi:10.11817/j.issn.1673-9248.2024.03.011

Abstract

Abstract:

Objective

To investigate the correlation between high sensitivity C-reactive protein (hs-CRP), lipoprotein-associated phospholipase A2 (Lp-PLA2), and calcium-binding protein β (S100β) and cognitive impairment in patients with ischemic small cerebral vascular disease (CSVD).

Methods

A total of 80 patients with ischemic CSVD were collected as observation group and were divided into non-cognitive impairment and cognitive impairment groups according to the score of Montreal cognitive assessment (MoCA). An additional 40 healthy people were selected as the healthy control group. Serum levels of hs-CRP, Lp-PLA2, and S100β in patients with ischemic CSVD and healthy people were measured. The levels of hs-CRP, Lp-PLA2, and S100β were analyzed using one-way Anova, followed by Logistic multiple regression analysis and Spearman correlation analysis to determine their correlation.

Results

There were no significant differences in general conditions among the three groups. The serum levels of hs-CRP, Lp-PLA2, and S100β in patients with cognitive impairment [(7.6±4.01) ng/ml, (55.77±35.59) pg/ml, (0.66±0.047) μg/L] were higher than those in patients without cognitive impairment [(4.35±3.99) ng/ml, (37.71±8.45) pg/ml, (0.62±0.058) μg/L] and in healthy controls [(1.13±0.84) ng/ml, (24.10±3.16) pg/ml, (0.56±0.039) μg/L]. Logistic regression analysis showed that serum hs-CRP, Lp-PLA2, and S100β were independent risk factors for cognitive impairment in patients with CSVD (OR=2.619, P<0.001; OR=1.814, P<0.001; OR=2.340, P<0.001). hs-CRP, Lp-PLA2, and S100β were negatively correlated with MoCA scores (r=-0.533, r=-0.263, r=-0.369; all P<0.05).

Conclusion

hs-CRP, Lp-PLA2, S100β were negatively correlated with the cognitive function in CSVD and were identified independent risk factors.

Key words: Cerebral small vascular disease, Vascular cognitive impairment, High sensitivity C-reactive protein, Lipoprotein-associated phospholipase A2, Calcium-binding protein β

Chunying Ou, Xiaobin Li, Jing Guo, Ke Xu, Meng Wang, Xiaolei An. Correlation of hs-CRP, Lp-PLA2, and S100β with vascular cognitive impairment in patients with ischemic small vascular disease[J]. Chinese Journal of Cerebrovascular Diseases(Electronic Edition), 2024, 18(03): 265-269.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhnxgbzz.cma-cmc.com.cn/EN/10.11817/j.issn.1673-9248.2024.03.011

https://zhnxgbzz.cma-cmc.com.cn/EN/Y2024/V18/I03/265

Figures/Tables 3

项目	对照组（40例）	认知障碍组（48例）	非认知障碍组（32例）	统计值	P值
男/女（例）	24/16	28/20	18/14	χ²=0.103	0.950
年龄（岁， $x ¯ ± s$ ）	66.50±4.81	67.92±4.98	66.88±4.87	F=0.991	0.374
受教育年限（年， $x ¯ ± s$ ）	9.50±2.01	9.08±3.49	9.24±2.92	F=0.238	0.789
高血压病（例）	22	32	21	χ²=1.449	0.485
糖尿病（例）	6	12	8	χ²=1.571	0.456
高血脂（例）	19	26	17	χ²=0.425	0.808
冠心病（例）	3	6	4	χ²=0.690	0.708
高同型半胱氨酸血症（例）	4	18	10	χ²=8.906	0.012

项目	对照组（40例）	认知障碍组（48例）	非认知障碍组（32例）	统计值	P值
男/女（例）	24/16	28/20	18/14	χ²=0.103	0.950
年龄（岁， $x ¯ ± s$ ）	66.50±4.81	67.92±4.98	66.88±4.87	F=0.991	0.374
受教育年限（年， $x ¯ ± s$ ）	9.50±2.01	9.08±3.49	9.24±2.92	F=0.238	0.789
高血压病（例）	22	32	21	χ²=1.449	0.485
糖尿病（例）	6	12	8	χ²=1.571	0.456
高血脂（例）	19	26	17	χ²=0.425	0.808
冠心病（例）	3	6	4	χ²=0.690	0.708
高同型半胱氨酸血症（例）	4	18	10	χ²=8.906	0.012

组别	例数	hs-CRP（ng/ml）	Lp-PLA2（pg/ml）	S100β（μg/L）	MoCA评分（分）
对照组	40	1.13±0.84	24.10±3.16	0.56±0.039	29.20±0.52
认知障碍组	48	7.60±4.01^ab	55.77±35.59^ab	0.66±0.047^ab	18.71±3.71^ab
非认知障碍组	32	4.35±3.99^a	37.71±8.45^a	0.62±0.058^a	27.94±1.01
F值		60.529	20.896	58.337	239.91
P值		<0.001	<0.001	<0.001	<0.001

因素	β值	SE值	OR值	95%CI	P值
hs-CRP	0.963	0.259	2.619	1.575~4.355	<0.001
Lp-PLA2	0.608	0.170	1.814	1.051~2.181	<0.001
S100β	0.782	0.201	2.340	1.293~3.627	<0.001
Hcy	0.189	0.146	1.014	0.889~1.451	0.247

References 16

1	祁林瑞, 曾嵘, 胡风云. 炎性及代谢指标与脑小血管病认知障碍的相关性 [J/OL]. 中华脑血管病杂志(电子版), 2022, 16(1): 32-37.
2	刘洋, 王蕊, 张祥, 等. 症状性小动脉硬化脑小血管病患者脑微出血的危险因素分析 [J]. 中国卒中杂志, 2023, 18(4): 440-449.
3	Chojdak-Lukasiewicz J, Dziadkowiak E, Zimny A, et al. Cerebral small vessel disease: a review [J]. Adv Clin Exp Med, 2021, 30(3): 349-356.
4	Teng Z, Dong Y, Zhang D, et al. Cerebral small vessel disease and post-stroke cognitive impairment [J]. Int J Neurosci, 2017, 127(9): 824-830.
5	欧春影, 李传玲, 安晓雷, 等. 脑卒中后血管性认知功能障碍的危险因素分析及发病风险预测 [J]. 山东医药, 2019, 59(20): 68-71.
6	高晗清, 薛群, 段晓宇, 等. hs-CRP、Lp-PLA2联合CT血管造影在TIA及轻型脑卒中急性期疾病进展中的预测价值 [J]. 山东医药, 2017, 57(41): 85-87.
7	郭晖, 徐文君, 宋仁兴, 等. 支架取栓术后亚低温对急性大血管闭塞性缺血性脑卒中患者血清S100β蛋白水平的影响 [J/OL]. 中华脑血管病杂志(电子版), 2020, 14(05): 275-280.
8	彭斌. 在血管再通时代关注脑小血管病 [J]. 中国脑血管病杂志, 2019, 16(10): 505-507.
9	钟曦, 王伊龙. 血清生物标志物与脑小血管病关系研究进展 [J]. 中国卒中杂志, 2019, 14(11): 1140-1145.
10	Gilani STA, Khan DA, Rauf A, et al. Early diagnosis of coronary artery disease by inflammatory biomarkers of atherosclerosis in patients with angina [J]. J Interferon Cytokine Res, 2022, 42(9): 493-500.
11	田雨, 潘岳松, 管玲, 等. 高敏C反应蛋白与老年脑小血管病疾病总负荷的相关性 [J].中华老年心脑血管病杂志, 2021, 23(7): 720-723.
12	De Stefano A, Mannucci L, Tamburi F, et al. Lp-PLA2, a new biomarker of vascular disorders in metabolic diseases [J]. Int J lmmunopathol Pharmacol, 2019, 33: 1-4.
13	Santoso A, Heriansyah T, Rochman MS. Phosph01ipase A2 is an inflammatory predictor in cardiovascular diseases: is there any spacious room to prove the causation? [J]. Curr Cardiol Rev, 2020, 16(1): 3-10.
14	Zhu S, Wei X, Yang X, et al. P1asma lipoprotein—associated phospholipase A2 and superoxide dismutase are independent predicators of cognitive impairment in cerebral small vessel disease patients: diagnosis and assessment [J]. Aging Dis, 2019, 10(4): 834-846.
15	Sarkulova Z, Tokshilykova A, Sarkulov M, et al. [The level of s100β in blood serum as a prognostic factor of outcome in secondary brain lesions] [J]. Georgian Med News, 2021(321): 162-168.
16	Chen L, Chen L, Lv Y, et al. Tetrandrine ameliorates cognitive impairment via inhibiting astrocyte-derived S100B activation in a rat model of chronic cerebral hypoperfusion [J]. Neurol Res, 2013, 35(6): 614-621.

[1]	Yi-ting DU, Ruo-mei XU, Yi WANG, Wei SHEN. Significance of Detection of Serum Immunoglobulin M Combined With High Sensitivity C-Reactive Protein in Early Diagnosis of Neonatal Septicemia [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2010, 06(02): 107-109.
[2]	Zhiling Wang, Jiangyun Cai, Danhong Wang. Diagnostic value of neutrophil CD64 index combined with procalcitonin and hypersensitive C-reactive protein in neonatal intrauterine bacterial infection [J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2019, 13(05): 421-425.
[3]	Jinpei Lu. Effect of high sensitivity C-reactive protein combined with routine blood test in diagnosis of bacterial infectious diseases in children [J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2016, 10(05): 625-627.
[4]	Ruiyu Li, Xinliang Wang, Congcong Xu, Yanze Liu, Xuezhu Zhang. Analysis of the current status of domestic and international clinical trial registries for vascular cognitive impairment [J]. Chinese Journal of Brain Diseases and Rehabilitation(Electronic Edition), 2024, 14(01): 14-20.
[5]	Meng Zhang, Zhonghua Yu. Expression of serum adiponectin, Lp-PLA2, IL-17 and correlation analysis with cognitive function in patients with Alzheimer's disease [J]. Chinese Journal of Brain Diseases and Rehabilitation(Electronic Edition), 2023, 13(06): 358-363.
[6]	Chunying Ou, Chuanling Li, Xiaolei An, Xiaobin Li, Jing Guo, Ke Xu. Clinical analysis of the relationship between serum BDNF, IL-6, TNF-α levels and vascular cognitive impairment after acute cerebral infarction [J]. Chinese Journal of Brain Diseases and Rehabilitation(Electronic Edition), 2019, 09(03): 163-167.
[7]	Hui Wang, Jing Shi, Hetao Bian, Xiaotan Ji, Hongjuan Wang, Yang Xu, Zhongrui Yan. Protective effects of remote ischemic post conditioning on white matte in a mouse model of vascular cognitive impairment [J]. Chinese Journal of Brain Diseases and Rehabilitation(Electronic Edition), 2017, 07(01): 26-31.
[8]	Bin Zong, Bing Han, Xuefeng Zong. Relationship between lipoprotein-associated phospholipase A2 and ambulatory arterial stiffness index in patients with essential hypertension [J]. Chinese Journal of Clinicians(Electronic Edition), 2020, 14(09): 680-684.
[9]	Jianrong Wu, Yijing Ma, Chunmei Ma. Preliminary analysis of myeloperoxidase, oxidized low density lipoprotein and lipoprotein-associated phospholipase A2 in the plasma of healthy adults [J]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2016, 04(02): 116-121.
[10]	Jianwei Liu, Yan Wang. The relationship between cystatin C gene G73A locus and appolipoprotein E gene polymorphisms and vascular cognitive impairment [J]. Chinese Journal of Diagnostics(Electronic Edition), 2019, 07(02): 87-93.
[11]	Xiaoxiao Zhao, Jiating Qiu, Yishu Zhang, Rong Zhang, Peng Zhang, Xiaolei Liu. Application and prospect of Butylphthalide in the treatment of cognitive impairment [J]. Chinese Journal of Cerebrovascular Diseases(Electronic Edition), 2024, 18(01): 19-26.
[12]	Ganzhe Liu, Fen Ai. MiRNA-210 improved vascular cognitive impairment in rats by inhibiting HIF-1α expression [J]. Chinese Journal of Cerebrovascular Diseases(Electronic Edition), 2023, 17(05): 489-494.
[13]	Zhizhong Yang, Jingnian Ni, Mingqing Wei, Ting Li, Jing Shi, Jinzhou Tian. Research advances on aerobic exercise in the prevention of vascular cognitive impairment [J]. Chinese Journal of Cerebrovascular Diseases(Electronic Edition), 2022, 16(05): 299-304.
[14]	Yunfeng Han, Xuan Lai, Jun Yang, Changcheng Ma. Advances in the study of metabolic syndrome and vascular cognitive impairment [J]. Chinese Journal of Cerebrovascular Diseases(Electronic Edition), 2020, 14(04): 234-237.

Please choose a citation manager

Content to export